Difference between revisions of "Triclabendazole"

Revision as of 14:08, 6 July 2010

This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2009)

Triclabendazole (commercial names: veterinary, liquid: Fasinex; human, tablets: Egaten; both manufactured by Novartis) is a member of the Benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group.

Triclabendazole was initially only developed as an oral route drug and displays high efficacy against both immature and adult liver fluke.

It is generally accepted that benzimidazoles like triclabendazole bind to beta-tubulin and prevent the polymerisation of the microtubules of which they are part.

Since latter nineties, triclabendazole came into generic situation as patents expired in many countries. Many products were developed then. Among them, Trivantel® 15, a 15% triclabendazole suspension was launched by Agrovet Market Animal Health in earlies 2000. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched also by Agrovet Market Animal Health. The product: Fasiject® Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat Fasciola hepatica (both immature and adult liver fluke), roundworms and ectoparasites as well.

This pharmacology-related article is a stub. You can help ssf by expanding it. v d e

External links

• Fasiject® Plus (a brand of triclabendazole + ivermectin) Website
• Agrovet Market Animal Health Multilanguage Website
• Peruvian Agrovet Market Animal Health Website

cs:Triklabendazol de:Triclabendazol ja:トリクラベンダゾール